Chava Perry

Title: Chava Perry: Innovator in Hematopoietic Cell Differentiation

Introduction

Chava Perry is a notable inventor based in Ramat Gan, Israel. He has made significant contributions to the field of hematopoietic cell differentiation through his innovative research and patents. His work focuses on the use of peptides to induce granulocytopoiesis, which has important implications for medical treatments.

Latest Patents

Chava Perry holds a patent titled "Acetylcholinesterase (ACHE)-derived peptide as an inducer of granulocytopoiesis, uses and methods thereof." This invention describes the use of an AChE-R-derived peptide, also known as ARP, as an inducer of hemopoietic cell differentiation and expansion, specifically for the granulocytic population. The patent also presents the use of ARP as an inducer of thrombopoietin and pro-inflammatory cytokines. Furthermore, ARP may be utilized in the pre-transplant priming of hematopoietic stem cells, showcasing its potential in various medical applications.

Career Highlights

Throughout his career, Chava Perry has worked with esteemed organizations such as Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. and the Medical Research Fund at the Tel Aviv Sourasky Medical Center. His experience in these institutions has allowed him to advance his research and contribute to the scientific community.

Collaborations

Chava Perry has collaborated with notable colleagues, including Hermona Soreq and Dan Grisaru. These partnerships have enriched his research and expanded the impact of his work in the field of hematopoietic cell differentiation.

Conclusion

Chava Perry's innovative work in the development of peptides for granulocytopoiesis represents a significant advancement in medical research. His contributions through patents and collaborations highlight the importance of innovation in the field of hematology.